Related by context. All words. (Click for frequent words.) 77 IV metastatic melanoma 74 IV NSCLC 71 IV malignant melanoma 71 stage IIIB 71 unresectable stage 70 stage IIIb 69 Stage IIB 68 leukemia AML 68 IIIA NSCLC 67 recurrent NSCLC 67 metastatic renal cell 67 mRCC 66 metastatic renal cell carcinoma 66 OvaRex ® MAb 66 medullary thyroid cancer 65 unresectable 65 stage IIIB IV 65 fallopian tube carcinoma 65 biliary tract cancer 65 nonsmall cell lung cancer 65 metastatic gastric 65 basal cell carcinoma BCC 65 Glioblastoma Multiforme 65 prostate cancer HRPC 65 metastatic malignant melanoma 65 tumors GIST 65 stage IIIb IV 64 refractory ovarian cancer 64 relapsed GBM 64 medically inoperable 64 IIIB NSCLC 64 nonmetastatic 64 lintuzumab SGN 64 platinum refractory 64 Ceflatonin 64 castration resistant prostate cancer 64 recurrent endometrial cancer 64 T1c 64 ovarian carcinoma 64 underwent resection 64 vemurafenib 64 prior chemotherapy regimens 64 NSCLC 64 prostate cancer CRPC 64 relapsed refractory multiple myeloma 64 metastatic bladder 64 localized renal 63 liver metastases 63 recurrent glioblastoma 63 Stage IIIb 63 MKC# MT 63 resistant ovarian cancer 63 receptor tyrosine kinase inhibitor 63 pancreatic adenocarcinoma 63 Hodgkin lymphoma HL 63 recurrent glioblastoma multiforme 63 including eniluracil ADH 63 prostate cancer mCRPC 63 Hepatocellular Carcinoma HCC 63 heavily pretreated 63 gastrointestinal stromal tumor GIST 63 metastatic malignant 63 Metastatic breast cancer 62 resectable 62 pancreatic carcinoma 62 lymphoid malignancies 62 epithelial ovarian cancer 62 metastatic colorectal 62 refractory CTCL 62 refractory prostate cancer 62 cell lymphoma CTCL 62 phase IIb clinical 62 epithelial ovarian 62 renal cell carcinoma 62 LHRH receptor positive 62 axitinib 62 mildly symptomatic 62 histologically confirmed 62 Aflibercept 62 stage IIIA 62 MAGE A3 ASCI 62 gemcitabine carboplatin 62 advanced NSCLC 62 pT3 62 pT2 62 systemic ALCL 62 multiple myeloma MM 62 metastatic HRPC 62 lymphoma CTCL 62 refractory acute myeloid 62 severe oral mucositis 62 relapsing remitting MS RRMS 62 refractory chronic lymphocytic 62 T1a 62 NSCL cancer 61 operable breast cancer 61 monoclonal antibody conjugated 61 chemoradiotherapy 61 ELACYT 61 leukemia CLL 61 metastatic castrate resistant 61 gefitinib Iressa 61 metastatic CRPC 61 invasive candidiasis 61 recurrent metastatic 61 refractory metastatic 61 gastrointestinal stromal tumors 61 cilengitide 61 advanced medullary thyroid 61 metastatic melanoma 61 HER2 positive metastatic breast 61 sunitinib Sutent 61 urothelial bladder cancer 61 metastatic sarcomas 61 myelodysplastic syndrome MDS 61 mycosis fungoides 61 metastatic RCC 61 taxane chemotherapy 61 superficial bladder cancer 61 HNSCC 61 Bayer HealthCare Onyx Pharmaceuticals 61 refractory colorectal cancer 61 registrational trial 61 baminercept 61 trastuzumab DM1 61 locoregional 61 sodium thiosulfate STS 61 CYT# potent vascular disrupting 61 valopicitabine 61 KRAS wild 61 oral ridaforolimus 61 docetaxel Taxotere ® 61 dacarbazine DTIC 61 pancreatic NET 61 indolent NHL 61 lymphocytosis 61 grade cervical intraepithelial 61 metastatic hormone refractory 61 PROSTVAC ® 61 PEG IFN 61 malignant ascites 61 antibody MAb 61 CLL SLL 61 EGFR TKI 61 Cloretazine 61 completely resected 61 hormone refractory 61 metastatic ovarian cancer 61 palliative radiotherapy 61 remission induction 61 Amrubicin 61 pertuzumab 61 refractory multiple myeloma 61 cytoreduction 61 forodesine 61 lupus nephritis 61 metastatic lung cancer 60 MGd 60 chronic HCV 60 metastatic pancreatic 60 HER2 positive breast cancer 60 MALT lymphoma 60 BRAF V#E mutation 60 LymphoStat B belimumab 60 metastatic colorectal cancer 60 non metastatic osteosarcoma 60 castrate resistant prostate cancer 60 Proxinium TM 60 refractory myeloma 60 BRIM3 60 resistant hormone refractory 60 aflibercept VEGF Trap 60 cetuximab Erbitux 60 Soft Tissue Sarcoma 60 metastatic GIST 60 neuroendocrine cancers 60 sorafenib Nexavar 60 NYHA Class II 60 systemic anaplastic large 60 eosinophilic asthma 60 Pemetrexed 60 malignant pleural mesothelioma 60 vandetanib 60 elacytarabine 60 tanespimycin 60 Nexavar sorafenib 60 myelofibrosis MF 60 phase IIb trial 60 EGFR mutation positive 60 recurrent malignant glioma 60 leukemia ALL 60 seminoma 60 thymalfasin 60 Cell Lymphoma CTCL 60 dasatinib Sprycel ® 60 metastatic carcinoma 60 hormone refractory prostate cancer 60 opioid induced constipation OIC 60 Cutaneous T 60 dermatology biopharmaceutical company 60 refractory cutaneous T 60 refractory AML 60 nasopharyngeal carcinoma 60 myelodysplastic syndromes MDS 60 pain palliation 60 refractory CLL 60 Peginterferon alfa 2b 60 myelofibrosis 60 Relapsed Refractory 60 phase IIa 60 IMA# 60 HBeAg negative 60 IIIb 60 plus gemcitabine 60 Bezielle 60 chemoradiation therapy 60 cutaneous melanoma 60 gastric adenocarcinoma 60 relapsed ovarian cancer 60 Allovectin 7 60 Exherin TM 60 OncoVEX GM CSF 60 PEGylated interferon beta 1a 60 mCRC patients 60 Evoltra ® 60 acute myelogenous leukemia AML 60 Brentuximab Vedotin SGN 60 mg/m2 dose 60 Hodgkin lymphoma NHL 60 relapsed MM 60 pediatric acute lymphoblastic 60 HRPC 60 Sprycel dasatinib 60 ABSORB trial 60 multicenter Phase 60 Zolinza 60 T#I [002] 60 recurrent colorectal cancer 60 acute myeloid 59 Torisel 59 curative resection 59 lymph node involvement 59 cytologically confirmed 59 mapatumumab 59 Advanced Melanoma 59 HCV genotype 59 Phase IIb clinical trials 59 Waldenstrom macroglobulinemia 59 metastatic CRC 59 hepatocellular cancer 59 Campath alemtuzumab 59 demonstrated antitumor activity 59 cetuximab Erbitux ® 59 hepatitis C HCV 59 cabazitaxel 59 heterozygous FH 59 phase IIb study 59 gastrointestinal stromal tumors GIST 59 cervical dysplasia 59 recurrent squamous cell carcinoma 59 thymoma 59 refractory metastatic colorectal cancer 59 symptomatic BPH 59 budesonide foam 59 metastatic renal 59 DEB# 59 metastatic pancreatic cancer 59 TORISEL 59 unresectable locally advanced 59 hepatocellular carcinoma HCC 59 K ras mutations 59 Acute Myeloid Leukaemia AML 59 Diamyd ® 59 prostate adenocarcinoma 59 carcinoid tumors 59 distant metastases 59 steroid refractory GvHD 59 BRAF V# mutation 59 relapsing multiple sclerosis 59 metastatic colorectal carcinoma 59 elotuzumab 59 Myelodysplastic Syndrome MDS 59 Acute Myeloid Leukemia AML 59 Epratuzumab 59 5 fluorouracil leucovorin 59 rindopepimut 59 galiximab 59 minimally symptomatic 59 IRX 2 59 previously untreated follicular 59 Sezary syndrome 59 hepatitis C genotype 59 astrocytoma 59 Temsirolimus 59 papillary renal cell carcinoma 59 postoperative chemotherapy 59 colorectal cancer liver metastases 59 Sutent sunitinib 59 Allovectin 7 ® 59 unresectable tumors 59 B CLL 59 commercialize deforolimus 59 cervical carcinoma 59 multicenter phase 59 leukemia APL 59 efaproxiral 59 Ozarelix 59 recurrent glioblastoma multiforme GBM 59 idiopathic thrombocytopenic purpura ITP 59 assessing T DM1 59 Cell Lymphoma 59 autoantibody positive 59 BRIM2 59 dosing cohort 59 TACI Ig 59 relapsed AML 59 liposomal amphotericin B 59 PANVAC VF 59 esophageal candidiasis 59 RANK Ligand inhibitor 59 PROSTVAC TM 59 renal carcinoma 59 refractory gout 59 Pivotal Phase III 59 Phase 2b Clinical Trial 59 advanced hepatocellular carcinoma 59 ALN VSP Phase 59 prostate carcinoma 59 non squamous NSCLC 59 refractory NSCLC 59 CTAP# Capsules 59 Metastatic Colorectal Cancer 59 Hormone Refractory Prostate Cancer 59 metastatic kidney 59 cytogenetic responses 59 indolent follicular non 59 neoadjuvant chemotherapy 59 dasatinib Sprycel 59 underwent liver transplantation 59 colorectal carcinoma 59 Rituxan rituximab 59 Randomized Phase 59 Chronic Lymphocytic Leukemia CLL 59 liposomal doxorubicin 59 ixabepilone 59 recurrent GBM 59 underwent surgical resection 59 decompensated liver disease 59 docetaxel Taxotere R 59 tuberous sclerosis TS 59 SHPT 59 Amigal TM 59 OvaRex R 59 pheochromocytoma 59 HGS ETR1 59 Follicular Lymphoma 59 metastatic castration resistant 59 immune thrombocytopenic purpura ITP 59 Cloretazine ® 59 subependymal giant cell 59 HER2 positive 58 hypercholesterolemic patients 58 locoregional recurrence 58 FOLOTYN ® 58 anthracycline taxane 58 BrachySil TM 58 gemcitabine chemotherapy 58 Alocrest 58 pegylated interferon alfa 2a 58 lymph node metastases 58 smoldering myeloma 58 BR.# 58 chronic myeloid 58 UPLYSO 58 treatment naïve genotype 58 castrate resistant 58 OncoVAX ® 58 phase Ib 58 severe hypercholesterolemia 58 cholangiocarcinoma 58 dose cohort 58 relapsed leukemia 58 Dacogen injection 58 CMV disease 58 CytoFab ™ 58 homozygous FH 58 colon carcinoma 58 Metastatic Melanoma 58 adjuvant therapy 58 Safinamide 58 alvespimycin 58 hormone refractory metastatic prostate 58 Panzem R NCD 58 gemcitabine Gemzar ® 58 Canvaxin 58 BRAF inhibitor 58 intraepithelial neoplasia 58 Combination REOLYSIN R 58 chronic lymphocytic leukemia CLL 58 CML CP 58 VEGFR2 inhibitor 58 ipsilateral breast 58 haematological cancers 58 evaluable 58 peritoneal cancer 58 colorectal liver metastases 58 Doxil ® 58 huN# DM1 58 urothelial carcinoma 58 glufosfamide 58 bendamustine 58 OncoVex 58 BRCA deficient 58 Malignant Melanoma 58 #mg BID [001] 58 metastatic disease 58 weekly subcutaneous injections 58 HeFH 58 metaglidasen 58 Aplidin 58 metastatic colon cancer 58 ACTEMRA TM 58 Acute Radiation Syndrome ARS 58 satraplatin Phase 58 AVASTIN 58 Gleevec imatinib 58 untreated metastatic melanoma 58 PCNSL 58 amrubicin 58 visceral metastases 58 cutaneous squamous cell carcinoma 58 Yervoy 58 homozygous familial hypercholesterolemia 58 EGFR mutations 58 CABP 58 non splenectomized 58 unresectable Stage III 58 idiopathic thrombocytopenic purpura 58 PEGylated Fab fragment 58 naïve HCV 58 AEG# 58 IL# PE#QQR 58 peritoneal carcinomatosis 58 relapsed multiple myeloma 58 Surgical resection 58 imatinib therapy 58 Omnitarg 58 Zybrestat 58 hepatorenal syndrome 58 radiation sensitizer 58 pediatric pontine glioma 58 unresectable liver cancer 58 relapsed Hodgkin lymphoma 58 Folfox 58 Mipomersen 58 Nexavar tablets 58 evaluating T DM1 58 rALLy clinical trial 58 imatinib Gleevec ® 58 BARACLUDE ® 58 haematologic 58 cutaneous T 58 cytokine refractory 58 erlotinib Tarceva ® 58 HER2 negative 58 invasive carcinoma 58 randomized #:#:# 58 INCB# [003] 58 MYCN amplification 58 non resectable 58 Behcet uveitis 58 chronic HCV genotype 58 obatoclax 58 HuMax CD4 58 recurrent ovarian cancer 58 PAOD 58 INCB# [001] 58 darapladib 58 juvenile idiopathic arthritis 58 riociguat 58 dose cohorts 58 genotype 1a 58 Insegia 58 Myelodysplastic Syndrome 58 paclitaxel poliglumex 58 erlotinib Tarceva 58 imatinib resistant 58 Prodarsan R 58 investigational monoclonal antibody 58 metastatic cancer 58 myelodysplastic myeloproliferative diseases 58 prostate cancer AIPC 58 liposomal formulation 58 Median survival 58 fluoropyrimidine 58 virus HCV protease inhibitor 58 GW# [003] 58 taxane resistant 58 catheter occlusion 58 Advaxis Phase 58 Wilms tumors 58 IMGN# 58 transitional cell carcinoma 58 advanced carcinoid 58 lymphadenectomy 58 soft tissue sarcoma 58 iniparib 58 vismodegib 58 oral nucleoside analogue 57 Acute Myelogenous Leukemia AML 57 trastuzumab Herceptin R 57 Neuvenge 57 randomized multicenter trial 57 Adjuvant chemotherapy 57 ospemifene 57 brain metastases 57 Rindopepimut 57 epithelial tumors 57 Annamycin 57 patientswith 57 T#I mutation 57 huC# DM4 57 taxane refractory 57 subcutaneous methylnaltrexone 57 Jevtana 57 thalidomide Thalomid 57 omacetaxine mepesuccinate 57 targeted radiotherapeutic 57 dose escalation clinical 57 chlorambucil 57 null responder 57 STRIDE PD 57 adjuvant radiotherapy 57 Kit CD# positive 57 rituximab refractory 57 BENLYSTA ® 57 chronic myeloid leukemia CML 57 TRO# 57 ZACTIMA 57 multicenter Phase II 57 gastrointestinal stromal tumor 57 standard chemotherapy regimen 57 humanised monoclonal antibody 57 Gleevec imatinib mesylate 57 Non Hodgkin 57 MELAS 57 non constipating irritable 57 FOLFOX4 57 Atypical Hemolytic Uremic Syndrome 57 trabectedin 57 phase IIb 57 rALLy 57 clinically localized prostate 57 oral prodrug 57 FOLFOX6 57 pan HDAC inhibitor 57 fistulizing Crohn disease 57 paclitaxel cisplatin 57 SCCHN 57 cell lymphoma ALCL 57 antiretroviral naïve 57 Meets Primary Endpoint 57 randomized controlled Phase 57 EndoTAGTM 1 57 SNT MC# 57 Neovascular AMD 57 leiomyosarcoma 57 hA# 57 breast carcinomas 57 follicular lymphoma 57 anthracyclines taxanes 57 PNP inhibitor 57 paclitaxel carboplatin 57 cell carcinoma RCC 57 oblimersen 57 TTR amyloidosis 57 Phase Ib study 57 relapsed refractory 57 RCW breast cancer 57 Fludara 57 cediranib 57 adecatumumab 57 small lymphocytic lymphoma 57 Phenoptin 57 lumiliximab 57 Elagolix 57 carboplatin paclitaxel 57 farletuzumab 57 non alcoholic steatohepatitis 57 transthyretin amyloidosis 57 Virulizin ® 57 refractory APL 57 Gleevec resistant 57 dose escalation phase 57 Pivotal Phase II 57 acute lymphoblastic 57 Orphan Status 57 Chronic Myelogenous Leukemia CML 57 Pivotal Trial 57 severe neutropenia 57 surgically resectable 57 MAGE A3 57 myeloid metaplasia 57 Iluvien ® 57 grade cervical dysplasia 57 Prednisone Against Refractory 57 squamous cell 57 Pralatrexate 57 generation purine nucleoside 57 gemcitabine cisplatin 57 PROSTVAC VF 57 adjuvant chemotherapy 57 relapsing remitting multiple sclerosis 57 alkylating agent 57 pulmonary metastases 57 pancreatic neuroendocrine tumors 57 Chronic Myeloid Leukemia 57 Multiple Myeloma MM 57 RG# [001] 57 squamous histology 57 Fx #A 57 Alessandro Riva 57 Darusentan 57 HIV HCV coinfected 57 macroalbuminuria 57 cetuximab Erbitux R 57 taxane therapy 57 smoldering multiple myeloma 57 squamous cell carcinoma SCC 57 posaconazole 57 diagnosed GBM 57 CTCL 57 mertansine 57 relapsing remitting MS 57 Vascular Disrupting Agent 57 AEGR 57 PSMA ADC 57 refractory indolent non 57 ribavirin RBV 57 trastuzumab DM1 T DM1 57 cell lung cancer 57 Evoltra TM 57 ATL# [001] 57 LymphoStat B TM 57 genotype 1b 57 tumor histology 57 systemically administered 57 atypical hemolytic uremic syndrome 57 gastric carcinoma 57 IIb clinical trial 57 metastatic 57 dexpramipexole 57 anthracycline containing 57 carcinoma mCRC 57 posterior uveitis 57 achieved CCyR 57 TMC# C# 57 Chronic Lymphocytic Leukemia 57 diabetic neuropathic pain 57 haematologic malignancies 57 breast carcinoma 57 cutaneous T cell 57 TEMODAL 57 terlipressin 57 hematologic disorders 57 initiate Phase 1b 57 pretransplant 57 recurrent ovarian 57 pegylated liposomal doxorubicin 57 fallopian tube cancers 57 bladder carcinoma 57 Diabetic Macular Edema DME 57 androgen independent 57 cytotoxic therapy 57 delivers fluocinolone acetonide FA 57 randomized Phase IIb 57 adjuvant radiation 57 SUPPRELIN R LA 57 histological subtype 57 hepatocellular carcinoma 57 KRAS mutation 57 grade dysplasia 57 unresectable malignant mesothelioma UMM 57 Arranon 57 IMC A# 57 induced macular edema 57 Myelofibrosis 57 chronic plaque psoriasis 57 Flu Cy 57 extracapsular extension 57 refractory lymphoma 57 Vicinium TM 57 hematological malignancy 57 neoadjuvant therapy 57 follicular lymphoma FL 57 Ceflatonin R 57 docetaxel chemotherapy 57 Plicera 57 RSR# 57 familial amyloidotic polyneuropathy FAP 57 Aurexis 57 Lenocta 57 leukemia CML 57 PEGINTRON TM 57 metastatic HER2 positive 57 iniparib BSI 57 keloid scarring 57 ILUVIEN ® 57 vinorelbine tartrate 57 HQK 57 virologic failure 57 Rhucin ® recombinant 57 GnRH agonist 57 evaluating tivozanib 57 SAI EGF 57 non squamous 57 de novo kidney transplant 57 refractory Hodgkin lymphoma 57 Proellex TM 57 5-FU/LV 57 transplantation HCT 57 hoFH 57 YONDELIS 57 glioblastoma 57 bevacizumab Avastin ® 57 recurrent metastatic ovarian cancer 57 Torisel temsirolimus 57 myeloproliferative disorders 57 primary hypercholesterolemia 57 colorectal liver 57 VNP#M 57 CHOP chemotherapy 57 prostate cancer PCa 57 mitoxantrone plus 57 systemic lupus erythematosus SLE 57 anti EGFR antibody 56 Sudhir Agrawal D.Phil 56 Tesetaxel 56 Cell Lung Cancer 56 HBeAg positive patients 56 pediatric malignancies 56 Phase IIb trials 56 ZACTIMA TM ZD# 56 IBS C 56 chronic angina 56 ancrod 56 biochemical relapse 56 rapid virologic response 56 lintuzumab 56 histologic subtype 56 relapsed ALL 56 mTOR inhibitor 56 luteinizing hormone releasing 56 Epothilone D 56 lobular carcinoma 56 chemotherapy cisplatin 56 Arzerra ofatumumab 56 grade glioma 56 non hodgkin lymphoma 56 malignant lymphoma 56 Chronic Myeloid Leukemia CML 56 registrational 56 diabetic nephropathy 56 Troxatyl 56 OHR/AVR# 56 Systemic Sclerosis 56 cisplatin chemotherapy 56 low dose cytarabine 56 achieved ACR# 56 temsirolimus 56 carcinoid syndrome 56 IMC #B 56 solanezumab 56 Telintra 56 ALN PCS 56 chronic myelogenous leukemia CML 56 oral clodronate 56 doublet chemotherapy 56 medullary thyroid carcinoma 56 Omacetaxine 56 ATTR PN 56 GSK# [001] 56 EGFR inhibitors 56 HCV RESPOND 2 56 sorafenib Nexavar ® 56 ThermoDox R 56 neoadjuvant 56 myelogenous leukemia 56 alemtuzumab Campath 56 histone deacetylase HDAC inhibitor 56 differentiated thyroid 56 refractory acute promyelocytic 56 essential thrombocythemia ET 56 Acute myeloid leukemia 56 PrevOnco 56 Velcade bortezomib 56 multicentric 56 evaluable subjects 56 trastuzumab emtansine T DM1 56 cancer mCRC 56 complement inhibitor eculizumab 56 essential thrombocythemia 56 Trial Evaluating 56 PRTX 56 midstage trials 56 nodal metastasis 56 metastatic prostate cancer 56 plus dexamethasone 56 estramustine 56 complete cytogenetic 56 pediatric Crohn disease 56 Viramidine 56 taxane chemotherapy administered 56 Pafuramidine 56 CCR5 mAb 56 secondary hyperparathyroidism 56 Fibrillex TM 56 MKC# MKC# PP 56 tumor recurrence 56 retinal vein occlusion induced 56 measurable tumor regressions 56 Halaven 56 liver metastasis 56 azacitidine 56 metastatic sarcoma 56 novel therapeutic antibodies 56 CR nPR 56 phase IIa clinical 56 intravenous iclaprim 56 oral deforolimus 56 investigational oral hepatitis C 56 sarcomatoid 56 metastatic medullary thyroid 56 nonalcoholic steatohepatitis NASH 56 Pivotal Phase 56 noninfectious uveitis 56 figitumumab 56 Tarceva TM 56 hepatic metastases 56 eribulin mesylate 56 geographic atrophy 56 TKI therapy 56 Pegylated Interferon 56 Trofex 56 dasatinib 56 ADXS# 56 infusional 5-FU/LV 56 GALNS 56 anti angiogenic therapy 56 PD LID 56 5-fluorouracil/leucovorin 56 Phase IIa trial 56 Papillary 56 phase III isavuconazole 56 AzaSite Plus 56 advanced unresectable 56 systemic fungal infections 56 distant metastasis 56 Cetrorelix 56 advanced adenomas 56 precancerous cervical lesions 56 acetonide FA 56 Phase III randomized controlled 56 elvucitabine 56 neuroendocrine tumors 56 Acute Coronary Syndromes ACS 56 pemphigus vulgaris 56 cinacalcet HCl 56 CR# vcMMAE 56 bone marrow reticulin deposition 56 proliferative retinopathy 56 advanced epithelial ovarian 56 DCVax R Brain 56 sunitinib 56 Carcinoid Syndrome 56 TELINTRA 56 talactoferrin 56 situ LCIS 56 Adjuvant Treatment 56 myelodysplastic syndromes 56 Alemtuzumab 56 hypereosinophilic syndrome 56 briakinumab 56 ara C 56 OvaRex 56 Kamada AAT 56 IIa trial 56 temozolomide Temodar 56 recurrent glioma 56 Fodosine 56 prognostic variables 56 ofatumumab HuMax CD# 56 Letairis ambrisentan 56 surgically resected 56 hematopoietic cancers 56 Onrigin 56 ductal adenocarcinoma 56 total thyroidectomy 56 oral Hycamtin 56 Selective Internal 56 TASQ 56 novel VDA molecule 56 PI3K/Akt pathway inhibitor 56 methylnaltrexone 56 metastatic breast cancer 56 Corlux 56 ADVEXIN therapy 56 familial hypercholesterolemia FH 56 AP# [003] 56 pCR 56 myeloproliferative diseases 56 TroVax ® 56 hematological cancers 56 diarrhea predominant irritable 56 axillary lymph nodes 56 nilotinib 56 ductal carcinomas 56 chronic GVHD 56 Carcinoma 56 SJIA 56 HBeAg negative patients 56 VFEND 56 Bayer Nexavar 56 alpha folate receptor 56 L BLP# 56 Prodarsan 56 MPS IVA 56 corticosteroid dexamethasone 56 MAXY alpha 56 Vidaza azacitidine 56 ocrelizumab 56 Archexin 56 neuroblastoma tumors 56 Amigal 56 Hepatocellular Carcinoma 56 ZADAXIN ® 56 undetectable HBV DNA 56 BENICAR HCT 56 evaluating mipomersen 56 de novo AML 56 deletion 5q 56 ponatinib 56 soft tissue sarcomas 56 QNEXA ® 56 motesanib 56 ankylosing spondylitis AS 56 alfa 2a 56 Phase #b/#a clinical 56 lorvotuzumab mertansine 56 autologous transplants 56 Cerebril TM 56 atherothrombotic events 56 cisplatin vinorelbine 56 panitumumab Vectibix 56 heFH 56 KRAS mutations occur 56 irinotecan containing 56 PRIMO CABG 56 Daclizumab 56 Severe Primary IGFD 56 mucinous 56 bardoxolone 56 myeloproliferative disorder 56 advanced metastatic renal 56 apremilast 56 EOquin TM 56 AA amyloidosis 56 bortezomib refractory 56 sapacitabine 56 metastatic carcinoid 56 overactive bladder syndrome 56 clazosentan 56 NEUMUNE 56 resected pancreatic cancer 56 Retreatment 56 TroVax 56 Irinotecan 56 omega interferon 56 Ophena TM 56 Phase 2b study 56 HuMax EGFr 56 whose tumors overexpress 56 OMNARIS HFA 56 capecitabine Xeloda 56 FOLFOX chemotherapy 56 B Cell Lymphoma 56 acute promyelocytic leukemia APL 56 Noxafil 56 Xyotax 56 ganetespib 56 unresectable recurrent 56 IgG1 monoclonal antibody 56 NMIBC 56 tramiprosate Alzhemed TM 56 histologies 56 progression TTP 56 TASKi3 56 Degarelix 56 systolic dysfunction